@SNSBank wordt er nog gewerkt aan een nieuw design voor de nieuwe app? Als het zo onoverzichtelijk blijft (terwijl de oude app gewoon goed was!), ga ik toch even kijken of ik kan overstappen naar een bank met een meer klantvriendelijke app.
Surprise!! 1989 (Taylor’s Version) is on its way to you 🔜! The 1989 album changed my life in countless ways, and it fills me with such excitement to announce that my version of it will be out October 27th. To be perfectly honest, this is my most FAVORITE re-record I’ve ever done because the 5 From The Vault tracks are so insane. I can’t believe they were ever left behind. But not for long! Pre order 1989 (Taylor’s Version) at https://t.co/12bONe9FJA 🩵😎🩵
📷: Beth Garrabrant
@MrBeast We'll play!
If you love libraries and reading and want to see more literate and educated Americans, hit that like button!
Plus, every $1 we raise helps secure over $1,600 in funding for libraries!
https://t.co/22TAUkCScO
You might be having a bad day, but at least your tweet wasn't seen by over a million people and only 26 (!!) people liked it.
That would be really emberrassing.
#PatientsNotPatents@sportswithjohn
It is false to suggest—as some recently have—that our patents are being used to prevent access to SIRTURO® (bedaquiline), our medicine for MDR-TB.
In fact, we have already entered into a collaboration with the Stop TB Partnership’s Global Drug Facility (“GDF”)—the largest procurer of TB medicines—which enables them to invite potential generic suppliers and purchase generic versions of SIRTURO® 100mg. On April 5, during a World Health Organization meeting, the GDF shared its intent to launch a tender for generic versions of SIRTURO® 100mg in the third quarter of 2023: https://t.co/6m49h5g7tn
In addition, we have shipped more than 660,000 courses of SIRTURO® to 159 countries since launch. Our patents made this possible, enabling us to assist countries to scale-up their use of our medicine responsibly and sustainably and invest in multiple, critical, anti-TB efforts. For instance, in the face of rising drug resistance, we support stewardship efforts that ensure MDR-TB patients can benefit from our medicine today and in the future.
Unfortunately, the most significant barrier to treatment access for patients today is the fact that millions of patients with TB go undiagnosed every year. This is a challenge that we have invested significant resources to overcome and must all get behind if we are to achieve the global goal of ending TB.
Absolutely agree that diagnosis is key to ending TB. One of the reasons we struggle with diagnosis, though, is because @JNJNews makes lifesaving treatment harder to access. Why work hard to diagnose a disease you can't treat?
JNJ are using the classic deflection tactic where they act like there is an enemy that we are equally against(undiagnosed TB)
When in fact THEY are public enemy number 1 and their patent is causing 1.6 million people a year to die from TB.
I AM LIVID
#PatientsNotPatents
Imagine having a chance to save millions of lives while boosting your brand image.
And instead you post in more detail how horrible you are as a company while falsely accusing your critics of lying and simply refuse to save human lives to make more money.
#PatientsNotPatents
It is false to suggest—as some recently have—that our patents are being used to prevent access to SIRTURO® (bedaquiline), our medicine for MDR-TB.
In fact, we have already entered into a collaboration with the Stop TB Partnership’s Global Drug Facility (“GDF”)—the largest procurer of TB medicines—which enables them to invite potential generic suppliers and purchase generic versions of SIRTURO® 100mg. On April 5, during a World Health Organization meeting, the GDF shared its intent to launch a tender for generic versions of SIRTURO® 100mg in the third quarter of 2023: https://t.co/6m49h5g7tn
In addition, we have shipped more than 660,000 courses of SIRTURO® to 159 countries since launch. Our patents made this possible, enabling us to assist countries to scale-up their use of our medicine responsibly and sustainably and invest in multiple, critical, anti-TB efforts. For instance, in the face of rising drug resistance, we support stewardship efforts that ensure MDR-TB patients can benefit from our medicine today and in the future.
Unfortunately, the most significant barrier to treatment access for patients today is the fact that millions of patients with TB go undiagnosed every year. This is a challenge that we have invested significant resources to overcome and must all get behind if we are to achieve the global goal of ending TB.
the absolute insanity it takes to brag about what your patents have done (made life-saving tb medication inaccessible to millions of sick people) and act like the world should be grateful for your greed... can't even put it into words.
Johnson & Johnson, the company that is actively trying to keep the cure for tuberculosis expensive and inaccessible by evergreening their patent on the cure in the countries that are most affected, tweeting this in june... Sickening. #PatientsNotPatents
Thank you @EditieNL for the apology.
Perhaps you could support our mission of education and let your audience know that the Memorial has an online lesson about the history of Auschwitz in Dutch.
Link: https://t.co/kwV4I6bgh8
In de strijd tegen polarisatie heeft de ChristenUnie haar steentje bijgedragen met een campagne filmpje waar iedereen hetzelfde over denkt. Namelijk: HUH.
Ik heb steeds meer moeite met de wijze waarop mensen met het syndroom van Down worden geëxploiteerd voor commercieel amusement. Tv-programma’s schetsen een volstrekt verkeerd beeld van Down en etaleren mensen met een beperking als een bezienswaardigheid.
Persoonlijk draadje: 🧵